Gene Therapy
Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.
131 stocks
| # | Name | Holding | Trade Value |
Theme Stocks |
% of Portfolio | Status | |
|---|---|---|---|---|---|---|---|
| 1451 |
Viking Global Investors
Stamford,
Connecticut
| $0 | -$52.7M | 0 | – | Closed |
|
| 1452 |
Waverly Advisors
Birmingham,
Alabama
| $0 | -$62K | 0 | – | Closed |
|
| 1453 |
Wealthfront
Palo Alto,
California
| $0 | -$138K | 0 | – | Closed |
|
| 1454 |
Westwood Holdings Group
Dallas,
Texas
| $0 | -$471K | 0 | – | Closed |
|
| 1455 |
WMC
Westwood Management Corporation
Chicago,
Illinois
| $0 | -$552K | 0 | – | Closed |
|
| 1456 |
WC
Wexford Capital
West Palm Beach,
Florida
| $0 | -$5.35M | 0 | – | Closed |
|
| 1457 |
WCM
Windsor Capital Management
Phoenix,
Arizona
| $0 | -$131K | 0 | – | Closed |
|
| 1458 |
YU
Yale University
New Haven,
Connecticut
| $0 | -$291K | 0 | – | Closed |
|
| 1459 |
ZDA
Zweig-DiMenna Associates
New York
| $0 | -$7M | 0 | – | Closed |
|